Streetbeat News

Analyst Ratings

SUM

JP Morgan analyst Adrian Heurta has downgraded Summit Materials (NYSE:SUM) from Neutral to Underweight, while raising the price target from $32 to $37.

Portfolio Pulse from richadhand@benzinga.com

July 06, 2023 | 9:32 am

EXP

JP Morgan analyst Adrian Huerta has downgraded Eagle Materials (NYSE:EXP) from Neutral to Underweight and raised the price target from $155 to $190.

Portfolio Pulse from richadhand@benzinga.com

July 06, 2023 | 9:31 am

VMC

JP Morgan analyst Adrian Huerta has downgraded Vulcan Materials (NYSE:VMC) from Overweight to Neutral, while raising the price target from $215 to $230.

Portfolio Pulse from richadhand@benzinga.com

July 06, 2023 | 9:30 am

MLM

JP Morgan analyst Adrian Heurta has downgraded Martin Marietta Materials (NYSE:MLM) from Overweight to Neutral, while raising the price target from $450 to $470.

Portfolio Pulse from richadhand@benzinga.com

July 06, 2023 | 9:29 am

AXP

Baird analyst David George has downgraded American Express (NYSE:AXP) from Outperform to Neutral and set a price target of $185.

Portfolio Pulse from richadhand@benzinga.com

July 06, 2023 | 9:27 am

AFRM

Piper Sandler analyst Kevin Barker has downgraded Affirm Holdings (NASDAQ:AFRM) from Neutral to Underweight and set a price target of $11.

Portfolio Pulse from richadhand@benzinga.com

July 06, 2023 | 9:26 am

THG

Piper Sandler analyst Paul Newsome has upgraded Hanover Insurance Gr (NYSE:THG) from Neutral to Overweight, but lowered the price target from $155 to $153.

Portfolio Pulse from richadhand@benzinga.com

July 06, 2023 | 9:25 am

SPT

Goldman Sachs analyst Chris Merwin has initiated coverage on Sprout Social (NASDAQ:SPT) with a Buy rating and a price target of $61.

Portfolio Pulse from richadhand@benzinga.com

July 06, 2023 | 9:02 am

MODN

Goldman Sachs analyst Adam Hotchkiss has initiated coverage on Model N (NYSE:MODN) with a Buy rating and a price target of $45.

Portfolio Pulse from richadhand@benzinga.com

July 06, 2023 | 9:02 am

NBIX

BMO Capital analyst Evan Seigerman has upgraded Neurocrine Biosciences (NASDAQ:NBIX) from Underperform to Market Perform and raised the price target from $91 to $96.

Portfolio Pulse from richadhand@benzinga.com

July 06, 2023 | 9:01 am